Venezuelan Scientist Develops Compounds to Fight Alzheimer’s and Parkinson’s

Recent scientific developments are introducing new strategies to combat neurodegenerative diseases, specifically Alzheimer’s and Parkinson’s. Researchers are exploring a variety of approaches, ranging from the repurposing of existing FDA-approved medications to the creation of novel compounds that target the epigenome of neurons.

Repurposing Cancer Drugs for Memory Restoration

In a study involving mouse models of Alzheimer’s, researchers identified that two FDA-approved cancer drugs may be capable of reversing the disease and restoring memory. The researchers used the Connectivity Map database of 1,300 FDA-approved drugs to find medications that could reverse Alzheimer’s-associated gene expression.

The study focused on letrozole, which is used to treat certain types of breast cancer in postmenopausal women, and irinotecan, an anti-cancer medication used for colon cancer and small cell lung cancer. When administered together in an aggressive Alzheimer’s mouse model, these drugs reversed disease-related gene expression signatures and dissolved toxic tau protein clumps.

According to the research, this combination prevented brain degeneration and restored learning and memory in mice that had already developed severe symptoms. To support these findings, researchers analyzed the medical records of 1.4 million patients and found that those who had taken letrozole or irinotecan for cancer were significantly less likely to develop Alzheimer’s.

Harnessing Natural Compounds from Herbs

Other research has focused on carnosic acid, a natural compound found in sage and rosemary. Scientists at Scripps Research created a stable form of this compound to test its effects on Alzheimer’s disease.

In mouse models, this modified rosemary and sage compound improved memory, boosted brain connections, and reduced harmful inflammation in the brain. These results suggest a potential new approach for treating the disease by addressing inflammation and enhancing cognitive function.

Epigenetic Reprogramming and Novel Compounds

Researchers at the Institute of Neurosciences in Barcelona have developed a novel compound known as FLAV-27. This compound differs from current Alzheimer’s treatments, which primarily focus on the removal of amyloid-beta plaques.

FLAV-27 targets a specific enzyme to therapeutically reprogram the epigenome of neurons. This involves modifying the molecular marks on DNA that change how genes function, thereby targeting the changes in gene expression that drive the progression of the disease.

While drugs targeting amyloid-beta plaques can slow the progression of Alzheimer’s if started early, there is currently no proven way to reverse cognitive decline. The development of FLAV-27 is intended to help pave the way for such a restorative therapy.

Diagnostics and Risk Factors

Alongside treatment research, advancements in diagnostics are helping distinguish between different types of dementia. An international consortium led by neurologist Charlotte Teunissen and researcher Katharina Bolsewig at UMC has validated a new spinal fluid biomarker, DOPA, which distinguishes Parkinson’s and Lewy body dementia from Alzheimer’s disease.

research into risk factors indicates a strong link between mental health and cognitive decline. Data suggests that depressed elderly adults are almost five times more likely to develop Alzheimer’s disease.

Ongoing Research in Neurodegenerative Diseases

Beyond the specific compounds mentioned, there is ongoing international effort to develop treatments for both Alzheimer’s and Parkinson’s. Recent reports highlight the work of Venezuelan scientists and researchers at the IVIC who are leading the synthesis of compounds designed to face these neurodegenerative challenges.